secwatch.observer — SEC 8-K summary
======================================

Issuer:     Medicus Pharma Ltd. (MDCX)
CIK:        0001997296
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001062993-25-010687
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Medicus Pharma prices $7M public offering of 2.26M units at $3.10/unit; closes June 2
--------------------------------------------------------------------------------

- Gross proceeds $7,006,000 from 2,260,000 units at $3.10/unit; each unit = 1 common share + 1 warrant.
- Warrants exercisable at $3.10/share, expire 5 years from issuance; not listed on exchange.
- Net proceeds to fund Phase 2 proof-of-concept trial for basal cell carcinoma using doxorubicin tip loaded dissolvable microarray needle skinpatch.
- Co. also issued $1.25M second-tranche debenture to Yorkville on June 2, 2025, bringing total Yorkville debentures to $2.5M.
- Placement agents Maxim, Brookline, D. Boral; cash fee 7.5% of gross proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1997296/000106299325010687/0001062993-25-010687-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1997296/000106299325010687/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001062993-25-010687

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer